(Q47608492)
Statements
A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease (English)
Przepiorka D
Phillips GL
Ratanatharathorn V
Cottler-Fox M
Sehn LH
Antin JH
LeBherz D
Awwad M
Hope J
1 December 1998